Tag: patients

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

MONTRÉAL, 02 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui qu’elle a conclu une convention d’arrangement contraignante avec CB Biotechnology, LLC (l’« Acquéreur »), un membre du même groupe que Future Pak, LLC (« Future Pak »), une société fermée de fabrication, de conditionnement et de distribution à façon de produits pharmaceutiques et nutraceutiques. Aux termes de la convention d’arrangement, l’Acquéreur acquerra toutes les actions ordinaires émises et en circulation de la Société pour 3,01 $ US par action en espèces, plus un droit conditionnel à la valeur (« DCV ») par action représentant des paiements supplémentaires totaux en espèces pouvant atteindre 1,19 $ US par DCV si certains jalons décrits plus en détail ci-après sont atteints (l’« Opération »). La contrepartie totale de l’Opération, en supposant le paiement intégral des DCV, se chiffre à 254 millions de dollars américains.

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized consumer rights law firm, is investigating potential claims against Ruffolo, Hooper & Associates, MD, PA (“Ruffolo, Hooper & Associates, MD, PA” or the “Company”) on behalf of Ruffolo, Hooper & Associates, MD, PA consumers. Our investigation concerns whether Ruffolo, Hooper & Associates, MD, PA has violated consumer protection laws and/or engaged in other unlawful business practices.

HIMS Investors with Losses Encouraged to Contact Hagens Berman

IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline

SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).